Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/19/2013US8399481 Compounds
03/19/2013US8399479 Modulators of cystic fibrosis transmembrane conductance regulator
03/19/2013US8399478 Thiophene-carboxamides useful as inhibitors of protein kinases
03/19/2013US8399477 (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
03/19/2013US8399476 Imidazo[1,2-a]pyridines and their use as pharmaceuticals
03/19/2013US8399475 Crystalline and amorphous forms of naltrexone hydrochloride
03/19/2013US8399474 Method of restoring the incretin effect
03/19/2013US8399473 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
03/19/2013US8399472 e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease
03/19/2013US8399470 Inhibitors of bruton's tyrosine kinase
03/19/2013US8399469 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
03/19/2013US8399468 Octahydro-pyrrolo[3,4-B]pyrrole derivatives
03/19/2013US8399467 Substituted triazolo-pyridazine derivatives
03/19/2013US8399466 Composition for regenerative treatment of cartilage disease
03/19/2013US8399465 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
03/19/2013US8399464 HSP90 inhibitor
03/19/2013US8399463 Imidazole derivatives
03/19/2013US8399462 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain
03/19/2013US8399461 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
03/19/2013US8399460 Chromenone derivatives
03/19/2013US8399459 1,4 oxazines as BACE1 and/or BACE2 inhibitors
03/19/2013US8399458 Compounds useful as protein kinase inhibitors
03/19/2013US8399457 Pharmaceutical compounds
03/19/2013US8399456 2,5-disubstituted arylsulfonamide CCR3 antagonists
03/19/2013US8399455 Compounds useful as chemokine receptor antagonists
03/19/2013US8399454 Azetidinyl diamides as monoacylglycerol lipase inhibitors
03/19/2013US8399453 Organic compounds
03/19/2013US8399452 Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
03/19/2013US8399451 Heterocyclic compounds
03/19/2013US8399450 Compounds and compositions as protein kinase inhibitors
03/19/2013US8399449 Fused heterocyclic derivative and use thereof
03/19/2013US8399448 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
03/19/2013US8399447 Metal triangulo compound and methods of using the same
03/19/2013US8399446 Methods of treating hypertriglyceridemia
03/19/2013US8399445 Acetylcysteine composition and uses thereof
03/19/2013US8399444 Bicyclic imidazole as DP1 receptor antagonists
03/19/2013US8399443 Treatment of hypertension by renal vascular delivery of guanethidine
03/19/2013US8399442 Pharmaceutical compounds
03/19/2013US8399441 Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
03/19/2013US8399440 Disease modifying anti-arthritic activity of 2-methoxyestradiol
03/19/2013US8399439 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
03/19/2013US8399438 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
03/19/2013US8399437 Methods for treating spinal muscular atrophy using tetracycline compounds
03/19/2013US8399436 N-pyrazolyl carboxamides as CRAC channel inhibitors
03/19/2013US8399435 Compounds for the treatment of proliferative disorders
03/19/2013US8399434 Method of activation of oxazaphosphorines
03/19/2013US8399433 Amino pyrimidine anticancer compounds
03/19/2013US8399432 Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
03/19/2013US8399431 Cyclodextrin-based polymers for therapeutics delivery
03/19/2013US8399430 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
03/19/2013US8399429 Uracyl cyclopropyl nucleotides
03/19/2013US8399428 Nucleosides with antiviral and anticancer activity
03/19/2013US8399426 Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA
03/19/2013US8399425 Alleviating neuropathic pain with EETs and sEH inhibitors
03/19/2013US8399424 Method for controlling the amount of gene product, and agent for controlling the amount of gene product
03/19/2013US8399420 Azacytidine analogues and uses thereof
03/19/2013US8399419 Antibacterial aminoglycoside analogs
03/19/2013US8399418 Monosebacate of pyrazole derivative
03/19/2013US8399414 Analgesics
03/19/2013US8399378 Use of neonicotinoids in pest control
03/19/2013US8399233 Histone deacetylases, and uses related thereto
03/19/2013US8399032 Bruise amelioration composition and method of use
03/19/2013US8399027 Silver coatings and methods of manufacture
03/19/2013US8399024 Water-insoluble medicine
03/19/2013US8399023 Crystallization method and bioavailability
03/19/2013US8399016 Sustained-release tablet composition of pramipexole
03/19/2013US8399015 Solid pharmaceutical dosage form
03/19/2013US8399007 Method for formulating a controlled-release pharmaceutical formulation
03/19/2013US8398997 Polylysine positively charged backbone, oligoarginine branching group, hydroxypropylcellulose viscosity modifying agent; treating wrinkles, hyperhidrosis, neurologic pain, migraine headache, reducing muscle spasms, preventing or reducing acne
03/19/2013US8398990 Glucan-based vaccines
03/19/2013US8398986 ADP-ribosylating toxin from listeria monocytogenes
03/19/2013US8398984 Removal promoters and inhibitor for apoptosis cells in vivo
03/19/2013US8398967 Particle formulations for use in pharmaceutical compositions
03/19/2013US8398963 Cosmetic agent
03/19/2013US8398958 Carotenoid compositions useful for whitening skin
03/19/2013US8398860 Method of purifying a surfactant by ultrafiltration
03/19/2013CA2733445C Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
03/19/2013CA2712783C Beta-lactamase inhibitors
03/19/2013CA2706872C Intermediates for the preparation of lipoxin a4 analogs
03/19/2013CA2684764C Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
03/19/2013CA2682629C Pyrimidine hydrazide compounds as pgds inhibitors
03/19/2013CA2660799C Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
03/19/2013CA2640339C Tamper resistant opioid dosage forms
03/19/2013CA2603817C Compositions containing micronized tanaproget prepared by wet granulation
03/19/2013CA2603806C Micronized tanaproget, compositions, and methods of preparing the same
03/19/2013CA2602444C Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
03/19/2013CA2594726C Heteroaryl sulfonamides and ccr2
03/19/2013CA2583634C Crosslinked amine polymers
03/19/2013CA2576191C T type calcium channel inhibitors
03/19/2013CA2569824C Phthalazine derivatives as parp inhibitors
03/19/2013CA2562406C Cyclic amine compound
03/19/2013CA2556227C Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
03/19/2013CA2549228C Hiv protease inhibiting compounds
03/19/2013CA2548572C Hydroxylamine derivatives
03/19/2013CA2538960C Cinnamoyl compound and use of the same
03/19/2013CA2537178C Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
03/19/2013CA2536086C Inhibition of dr3 in the treatment of allergic lung inflammation
03/19/2013CA2534313C Formulations containing an immune response modifier
03/19/2013CA2524027C Immunosuppressant compounds and compositions
03/19/2013CA2519969C Modified gum arabic
1 ... 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 ... 7860